5 July 2021 - Many of the new cancer drugs coming onto the market in Belgium are too expensive, and often ineffective, according to a new report from the Belgian Health Care Knowledge Centre.
The report, titled in English ‘Do innovative medicines against cancer always have a real added value?’ looks at two main issues: how anti-cancer drugs are supported by the arrangements in force to approve them and then make the cost reimbursable by health insurance.
And then: does the effect of the drugs justify the cost, as well as the hope given to the patients.